Gynica

Gynica is a women's health biopharmaceutical company developing a non-hormonal, cannabinoid-based therapy for endometriosis - a condition affecting 200 million women globally with no novel non-hormonal treatment in over 40 years.
The company's lead candidate, IntraVag® S301, is a proprietary drug candidate delivered via intravaginal suppository, targeting endometriosis-associated pelvic pain through a multi-mechanism, locally-acting approach. Gynica has completed a substantial preclinical package - including the world's first intravaginal cannabinoid animal study - establishing a de-risked foundation with a defined path to U.S. clinical development.
Beyond its therapeutic program, Gynica is also advancing commercial opportunities in the women's wellness, nutraceutical, and consumer health space, leveraging the same formulation and delivery infrastructure. Gynica's scientific team and advisory board include globally recognized KOLs in cannabinoid science, endometriosis, and general women's health.